FDA Approves Short Ragweed Pollen Allergen SL Tab - MPR
Help Your Patients Patient Information Coupons
The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck ), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis , with or without conjunctivitis. Ragwitek contains an extract from short ragweed (Ambrosia artemisiifolia) pollen.
Ragwitek is approved for use in adults 18 65 years of age. It is designed to help treat the underlying cause of allergic rhinitis by generating an immune response yohimbine to help protect against yohimbine targeted allergens.
The safety and effectiveness of Ragwitek was evaluated in approximately 1,700 adults. Of the 1,700 adults in the safety trial, about 760 were evaluated yohimbine to determine effectiveness. Some patients received Ragwitek while others received placebo. The patients reported their symptoms and additional yohimbine medications needed to get through the allergy season. During treatment for one ragweed pollen season, patients who received Ragwitek experienced about a 26% reduction in symptoms and the need for medications compared to those who received a placebo.
News Leukotriene modifier drug label change requested by FDA Xyzal gains expanded pediatric indication Claritin 12-Hour RediTabs available for allergies Children's Zyrtec Perfect Measure and Zyrtec Itchy Eye Drops available for allergies Claritin Liqui-Gels available for allergies
Related Articles Immunotherapy Tablet Under Review for Allergies FDA Approves Timothy Grass Pollen SL Tab First SL Allergy Immunotherapy Tablet Approved Phase 3 Study of Allergy Immunotherapy Tablet (AIT) for Ragweed Allergy Merck's BLA for Allergy Immunotherapy Tablet Accepted for Review
Activated Charcoal: Are There Benefits Beyond Poison Control? Low Dose NSAID Stool DNA Test: Effective for Colon Cancer Screening? Pharmacogenetic Considerations for Psychiatric Drugs How to Start a Subspecialty Clinic
Antibiotic Resistance Spurs Research Into Alternative Treatment Regimens yohimbine The Medicinal Uses of Monk Fruit Stool DNA Test: Effective for Colon Cancer Screening? Experts Weigh In: Omega-3s and Prostate Cancer Possessed by Possessions: Hoarding Disorder Diagnosis and Treatment
Activated Charcoal: Are There Benefits Beyond yohimbine Poison Control? Stool DNA Test: Effective for Colon Cancer Screening? Low Dose NSAID Pharmacogenetic Considerations for Psychiatric Drugs How to Start a Subspecialty Clinic
Help Your Patients Patient Information Coupons
The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck ), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis , with or without conjunctivitis. Ragwitek contains an extract from short ragweed (Ambrosia artemisiifolia) pollen.
Ragwitek is approved for use in adults 18 65 years of age. It is designed to help treat the underlying cause of allergic rhinitis by generating an immune response yohimbine to help protect against yohimbine targeted allergens.
The safety and effectiveness of Ragwitek was evaluated in approximately 1,700 adults. Of the 1,700 adults in the safety trial, about 760 were evaluated yohimbine to determine effectiveness. Some patients received Ragwitek while others received placebo. The patients reported their symptoms and additional yohimbine medications needed to get through the allergy season. During treatment for one ragweed pollen season, patients who received Ragwitek experienced about a 26% reduction in symptoms and the need for medications compared to those who received a placebo.
News Leukotriene modifier drug label change requested by FDA Xyzal gains expanded pediatric indication Claritin 12-Hour RediTabs available for allergies Children's Zyrtec Perfect Measure and Zyrtec Itchy Eye Drops available for allergies Claritin Liqui-Gels available for allergies
Related Articles Immunotherapy Tablet Under Review for Allergies FDA Approves Timothy Grass Pollen SL Tab First SL Allergy Immunotherapy Tablet Approved Phase 3 Study of Allergy Immunotherapy Tablet (AIT) for Ragweed Allergy Merck's BLA for Allergy Immunotherapy Tablet Accepted for Review
Activated Charcoal: Are There Benefits Beyond Poison Control? Low Dose NSAID Stool DNA Test: Effective for Colon Cancer Screening? Pharmacogenetic Considerations for Psychiatric Drugs How to Start a Subspecialty Clinic
Antibiotic Resistance Spurs Research Into Alternative Treatment Regimens yohimbine The Medicinal Uses of Monk Fruit Stool DNA Test: Effective for Colon Cancer Screening? Experts Weigh In: Omega-3s and Prostate Cancer Possessed by Possessions: Hoarding Disorder Diagnosis and Treatment
Activated Charcoal: Are There Benefits Beyond yohimbine Poison Control? Stool DNA Test: Effective for Colon Cancer Screening? Low Dose NSAID Pharmacogenetic Considerations for Psychiatric Drugs How to Start a Subspecialty Clinic
No comments:
Post a Comment